Faron Pharmaceuticals LTD: Holding(s) in Company

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) ⁱ

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ⁱⁱ:

Faron Pharmaceuticals Ltd

1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate)

Non-UK issuer

X

2. Reason for the notification (please mark the appropriate box or boxes with an “X”)

An acquisition or disposal of voting rights

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

X

Other (please specify) ⁱⁱⁱ: Amortisation of the First and Second Tranche Bonds with treasury shares

X

3. Details of person subject to the notification obligation ^iv

Name

Faron Pharmaceuticals Ltd

City and country of registered office (if applicable)

Turku, Finland

4. Full name of shareholder(s) (if different from 3.) ^v

Name

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reached ^vi:

3.8.2026

6. Date on which issuer notified (DD/MM/YYYY):

3.8.2026

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments
(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer (8.A + 8.B) ^vii

Resulting situation on the date on which threshold was crossed or reached

9.37%

9.37%

21,342,679

Position of previous notification (if
applicable)

10.97%

10.97%

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached ^viii

A: Voting rights attached to shares

Class/type of
shares
ISIN code (if possible)

Number of voting rights ^ix

% of voting rights

Direct
(DTR5.1)

Indirect
(DTR5.2.1)

Direct
(DTR5.1)

Indirect
(DTR5.2.1)

FI4000153309

21,342,679

9.37%

SUBTOTAL 8. A

21,342,679

9.37%

B 1: Financial Instruments according to DTR5.3.1R (1) (a)

Type of financial instrument

Expiration
date ^x

Exercise/
Conversion Period ^xi

Number of voting rights that may be acquired if the instrument is
exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)

Type of financial instrument

Expiration
date ^x

Exercise/
Conversion Period ^xi

Physical or cash
Settlement ^xii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

9. Information in relation to the person subject to the notification obligation (please mark the
applicable box with an “X”)

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer ^xiii

x

Full chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) ^xiv

Name ^xv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Faron Pharmaceuticals Ltd

9.37%

9.37%

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional information ^xvi

3.8.2026 Company announcement: Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Amortisation of the First and Second Tranche Bonds

Place of completion

Turku, Finland

Date of completion

3.8.2026